biotech

Bio-Analyst

Research Platform
person
arrow_backExplore/Omega-3
Tier-BPublic-ready6/26/2026

Omega-3

Glucose and metabolic health markers is closer to a research marker, so it should be read separately from a directly felt benefit.

Human evidence exists, but it is mostly in patient or disease contexts, so the score is handled conservatively.

Representative tier calculated from paper evidence that passed the collection audit.

Papers analyzed
87
Caution signal
Low
Representative score
74.2
Glucose and metabolic health markersCognition, memory, and focusImmune and respiratory support

Main benefit evidence

The representative ingredient tier is calculated from these target-level evidence groups.

Glucose and metabolic health
5 studiesTier-B
Glucose and metabolic health markers
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
56.7
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Cognition and focus
4 studiesTier-B
Cognition, memory, and focus
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Cognition and focus. These findings come from a defined study population, so everyday effects may differ.

Evidence score
54.6
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Immune and respiratory health
4 studiesTier-B
Immune and respiratory support
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Immune and respiratory health. These findings come from a defined study population, so everyday effects may differ.

Evidence score
54.6
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Stress and mood
4 studiesTier-B
Stress Response and Sleep Changes
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

These findings come from stress response, cortisol, anxiety, or sleep outcomes. They may mix felt benefits with physiological markers.

Evidence score
54.6
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Blood pressure and vascular health
3 studiesTier-B
Blood pressure and vascular health markers
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
52.0
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Blood lipids
3 studiesTier-B
Cholesterol and triglycerides
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.

Evidence score
52.0
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Recent research

Updated This Month10 new papers

Study dosage range (reference only)

Lower dose
1.2
g/day
Higher dose
4
g/day
Dosages used in research papers, shown as reference context.
Not personal dosing instructions, recommendations, or safety limits.

Key cautions to review

Standalone side-effect signals and combination cautions are listed separately.

Caution index
0.9
Caution band: Low
Caution signals
1
Side effects + combos + curated rules
Key precautions
No curated contraindication rule is available yet, but literature caution signals are shown below.
1 combo signals and 0 added-signal combos shown below.
Standalone side effects, combination cautions, and positive combos are separated below.

Standalone side effects

Adverse effect signal1 papers
A randomized clinical trial reported a small but statistically significant increase in the risk of depression or clinically relevant depressive symptoms with long-term marine omega-3 supplementation compared to placebo.human · unknown

Combinations studied together

The group showed a positive signal, but individual contributions are hard to isolate. Not a stack recommendation.

+비타민 EA 24-month RCT in cognitively healthy older adults found that a combination of omega-3 fatty acids, carotenoids, and vitamin E significantly reduced working memory errors compared to placebo, with effect sizes ranging from 0.090 to 0.105.

Evidence summaries

Paper IDs and full lists are private. Only study types and summaries are shown.

Key Evidence #1
Public scholarly dataCitation signal: 776
observational

Among statin-treated patients at high cardiovascular risk, the addition of omega-3 CA, compared with corn oil, to usual background therapies resulted in no significant difference in a composite outcome of major adverse cardiovascular events.

Key Evidence #2
Public scholarly dataCitation signal: 574
review

The pooled data suggest that omega-3 PUFA supplementation may decrease liver fat, however, the optimal dose is currently not known.

Key Evidence #3
Public scholarly dataCitation signal: 525
observational

The ongoing VITamin D and OmegA-3 TriaL (VITAL) is a large randomized, double-blind, placebo-controlled, 2×2 factorial trial of vitamin D and marine omega-3 fatty acids in the primary prevention of cancer and CVD among a multi-ethnic population of 20,000 U.S.

3 more summariesLimited representative sample by study type.
>
Public scholarly dataCitation signal: 525
review

The cumulative evidence from RCTs designed to assess the effect of omega-3 polyunsaturated fatty acid supplementation on clinical cardiovascular events is reviewed and prior recommendations for patients with prevalent coronary heart disease are updated.

Public scholarly dataCitation signal: 507
review

All the new sources have potentially important roles to play in increasing the supply of n-3 LC-PUFA so that they are available more widely and in higher concentrations providing more options and opportunities for human consumers to obtain sufficient EPA and D

Public scholarly dataCitation signal: 317
observational

Omega-3 FAs reduced cardiovascular mortality and improved cardiovascular outcomes and the cardiovascular risk reduction was more prominent with EPA monotherapy than with EPA+DHA therapy.

Omega-3
arrow_backBack to list